Newsletter
Newsletter Support JNS

Israeli medical-marijuana company plans Nasdaq listing

“We consider ourselves a pharma-grade cannabis leader and the major market for pharma players is Nasdaq,” said InterCure controlling shareholder Alex Rabinovitch.

Cannabis flower. Credit: Max Pixel/Creative Commons.
Cannabis flower. Credit: Max Pixel/Creative Commons.

The Israeli medical marijuana firm InterCure, whose chairman is none other than former Israeli Prime Minister Ehud Barak, has been planning to list itself on the Nasdaq stock exchange by mid-2019, controlling shareholder Alex Rabinovitch announced on Thursday.

“We consider ourselves a pharma-grade cannabis leader and the major market for pharma players is Nasdaq,” he said.

InterCure is already on the stock exchange in Tel Aviv, valued at $117 million, with its shares skyrocketing 1,300 percent so far in 2018.

The firm raised $12.1 million through a private funding round led by Rabinovitch and Gary Fegel, the founder of private-equity company GMF Capital.

It raised another $5 million last week with help from Israeli-American billionaire Adam Neumann, the CEO and co-founder of WeWork.

Approval from the Israeli government for the country’s cannabis industry to have export licenses remains pending.

The Berkeley project “has a record of promoting anti-Israel and antisemitic agendas,” Oleg Ivanov, of StandWithUs, told JNS. “We are deeply concerned that the same thing will happen in this training.”
The Federation told JNS exclusively that it is ending its engagement with a consultant who headed one of its communications projects after JNS reported that he advised attendees at a Federations conference to avoid using the word “Zionism.”
The U.S. president insists that American naval forces are maintaining a strict blockade until Tehran agrees to a deal or total surrender.
New York City’s request for proposal states that operators at the five city groceries must offer “kosher, halal, gluten free, dairy-free, vegan, diabetic options.”